Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 482
6
Diseases
14
Unique genes
0.225
Avg. similarity score
Vestibular disease
Most-connected disease (5 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Vestibular disease
Central vertigo
Deafness, autosomal recessive 84b
Peripheral vertigo
Deafness, autosomal recessive 36
Maleylacetoacetate isomerase deficiency
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Vestibular disease | 5 | 5 | 12 |
| Central vertigo | 3 | 3 | 5 |
| Deafness, autosomal recessive 84b | 3 | 3 | 1 |
| Peripheral vertigo | 3 | 3 | 5 |
| Deafness, autosomal recessive 36 | 1 | 1 | 1 |
| Maleylacetoacetate isomerase deficiency | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| OTOGL | 4 / 6 | Central vertigo, Deafness, autosomal recessive 84b, Peripheral vertigo, Vestibular disease |
| LYAR | 3 / 6 | Central vertigo, Peripheral vertigo, Vestibular disease |
| TMEM128 | 3 / 6 | Central vertigo, Peripheral vertigo, Vestibular disease |
| ESPN | 2 / 6 | Deafness, autosomal recessive 36, Vestibular disease |
| GSTZ1 | 2 / 6 | Maleylacetoacetate isomerase deficiency, Vestibular disease |
| QRSL1 | 2 / 6 | Central vertigo, Peripheral vertigo |
| ZNF91 | 2 / 6 | Central vertigo, Peripheral vertigo |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Glutathione conjugation | Reactome | 2 / 24 | 71.5× | 3.43e-4 | 5.00e-3 ✓ sig. |
| NOSIP mediated eNOS trafficking | Reactome | 1 / 2 | 429× | 2.33e-3 | 2.13e-2 ✓ sig. |
| Nitric oxide stimulates guanylate cyclase | Reactome | 1 / 3 | 286× | 3.49e-3 | 2.83e-2 ✓ sig. |
| Aldosterone synthesis and secretion | KEGG | 2 / 98 | 17.5× | 5.63e-3 | 3.95e-2 ✓ sig. |
| NOSTRIN mediated eNOS trafficking | Reactome | 1 / 5 | 172× | 5.82e-3 | 4.03e-2 ✓ sig. |
| Tyrosine catabolism | Reactome | 1 / 5 | 172× | 5.82e-3 | 4.03e-2 ✓ sig. |
| Fluid shear stress and atherosclerosis | KEGG | 2 / 141 | 12.2× | 1.14e-2 | 6.15e-2 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | Reactome | 1 / 11 | 78.0× | 1.28e-2 | 6.57e-2 |
| Oxytocin signaling pathway | KEGG | 2 / 154 | 11.1× | 1.34e-2 | 6.80e-2 |
| eNOS activation | Reactome | 1 / 13 | 66.0× | 1.51e-2 | 7.27e-2 |
| cGMP-PKG signaling pathway | KEGG | 2 / 166 | 10.3× | 1.55e-2 | 7.40e-2 |
| Regulation of pyruvate dehydrogenase (PDH) complex | Reactome | 1 / 16 | 53.6× | 1.85e-2 | 8.20e-2 |
| Arginine biosynthesis | KEGG | 1 / 23 | 37.3× | 2.65e-2 | 1.01e-1 |
| Proximal tubule bicarbonate reclamation | KEGG | 1 / 23 | 37.3× | 2.65e-2 | 1.01e-1 |
| VEGFR2 mediated vascular permeability | Reactome | 1 / 29 | 29.6× | 3.33e-2 | 1.15e-1 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| regulation of sodium ion transport | GO:0002028 | 2 / 19 | 141× | 8.85e-5 | 2.83e-3 ✓ sig. |
| sensory perception of sound | GO:0007605 | 3 / 162 | 24.7× | 2.17e-4 | 5.37e-3 ✓ sig. |
| glutathione metabolic process | GO:0006749 | 2 / 49 | 54.5× | 6.01e-4 | 1.08e-2 ✓ sig. |
| regulation of granulocyte chemotaxis | GO:0071622 | 1 / 1 | 1,335× | 7.49e-4 | 1.23e-2 ✓ sig. |
| vibrational conductance of sound to the inner ear | GO:0055127 | 1 / 1 | 1,335× | 7.49e-4 | 1.23e-2 ✓ sig. |
| nitric oxide storage | GO:0035732 | 1 / 1 | 1,335× | 7.49e-4 | 1.23e-2 ✓ sig. |
| negative regulation of glucocorticoid biosynthetic process | GO:0031947 | 1 / 1 | 1,335× | 7.49e-4 | 1.23e-2 ✓ sig. |
| microvillar actin bundle assembly | GO:0030034 | 1 / 1 | 1,335× | 7.49e-4 | 1.23e-2 ✓ sig. |
| positive regulation of phagocytosis | GO:0050766 | 2 / 58 | 46.0× | 8.41e-4 | 1.33e-2 ✓ sig. |
| cellular oxidant detoxification | GO:0098869 | 2 / 66 | 40.4× | 1.09e-3 | 1.53e-2 ✓ sig. |
| L-arabinose metabolic process | GO:0046373 | 1 / 2 | 667× | 1.50e-3 | 1.82e-2 ✓ sig. |
| positive regulation of striated muscle contraction | GO:0045989 | 1 / 2 | 667× | 1.50e-3 | 1.82e-2 ✓ sig. |
| regulation of the force of heart contraction by chemical signal | GO:0003057 | 1 / 2 | 667× | 1.50e-3 | 1.82e-2 ✓ sig. |
| smooth muscle hyperplasia | GO:0014806 | 1 / 2 | 667× | 1.50e-3 | 1.82e-2 ✓ sig. |
| negative regulation of muscle hyperplasia | GO:0014740 | 1 / 2 | 667× | 1.50e-3 | 1.82e-2 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Central vertigo | Peripheral vertigo | 0.833 | 5 | 1.35e-19 | 1.94e-18 ✓ sig. |
| Central vertigo | Vestibular disease | 0.200 | 3 | 3.55e-9 | 2.94e-8 ✓ sig. |
| Peripheral vertigo | Vestibular disease | 0.200 | 3 | 3.55e-9 | 2.94e-8 ✓ sig. |
| Central vertigo | Deafness, autosomal recessive 84b | 0.167 | 1 | 3.23e-4 | 6.41e-4 ✓ sig. |
| Deafness, autosomal recessive 84b | Peripheral vertigo | 0.167 | 1 | 3.23e-4 | 6.41e-4 ✓ sig. |
| Deafness, autosomal recessive 36 | Vestibular disease | 0.077 | 1 | 7.75e-4 | 1.25e-3 ✓ sig. |
| Deafness, autosomal recessive 84b | Vestibular disease | 0.077 | 1 | 7.75e-4 | 1.25e-3 ✓ sig. |
| Maleylacetoacetate isomerase deficiency | Vestibular disease | 0.077 | 1 | 7.75e-4 | 1.25e-3 ✓ sig. |